DE69835010T2 - Feststellung von endometriumkrebs - Google Patents

Feststellung von endometriumkrebs Download PDF

Info

Publication number
DE69835010T2
DE69835010T2 DE69835010T DE69835010T DE69835010T2 DE 69835010 T2 DE69835010 T2 DE 69835010T2 DE 69835010 T DE69835010 T DE 69835010T DE 69835010 T DE69835010 T DE 69835010T DE 69835010 T2 DE69835010 T2 DE 69835010T2
Authority
DE
Germany
Prior art keywords
mmp
uterine
endometrial cancer
activity
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69835010T
Other languages
German (de)
English (en)
Other versions
DE69835010D1 (de
Inventor
Alexander Richmont LOPATA
A. Lois Kew SALAMONSEN
A. Michael Kew QUINN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diagnotech Pty Ltd
Original Assignee
Diagnotech Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagnotech Pty Ltd filed Critical Diagnotech Pty Ltd
Publication of DE69835010D1 publication Critical patent/DE69835010D1/de
Application granted granted Critical
Publication of DE69835010T2 publication Critical patent/DE69835010T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69835010T 1997-03-20 1998-03-20 Feststellung von endometriumkrebs Expired - Lifetime DE69835010T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO5736A AUPO573697A0 (en) 1997-03-20 1997-03-20 Diagnosis of endometrial cancer
AUPO573697 1997-03-20
PCT/AU1998/000189 WO1998042865A1 (en) 1997-03-20 1998-03-20 Detection of endometrial cancer

Publications (2)

Publication Number Publication Date
DE69835010D1 DE69835010D1 (de) 2006-08-03
DE69835010T2 true DE69835010T2 (de) 2007-06-06

Family

ID=3800039

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69835010T Expired - Lifetime DE69835010T2 (de) 1997-03-20 1998-03-20 Feststellung von endometriumkrebs

Country Status (14)

Country Link
US (1) US6607894B1 (https=)
EP (1) EP0979304B1 (https=)
JP (2) JP4183757B2 (https=)
KR (1) KR20010006344A (https=)
CN (1) CN1257550A (https=)
AT (1) ATE331039T1 (https=)
AU (1) AUPO573697A0 (https=)
CA (1) CA2284099C (https=)
DE (1) DE69835010T2 (https=)
ES (1) ES2268767T3 (https=)
MY (1) MY119567A (https=)
NZ (1) NZ337868A (https=)
WO (1) WO1998042865A1 (https=)
ZA (1) ZA982403B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045147A1 (en) * 1998-03-05 1999-09-10 Diadexus Llc A novel method of detecting and monitoring endometrial and uterine cancers
AUPQ219799A0 (en) 1999-08-13 1999-09-02 R. Lurie Pty Ltd Apparatus for obtaining potological samples
US7071164B2 (en) 2001-08-16 2006-07-04 Kimberly-Clark Worldwide, Inc. Anti-cancer and wound healing compounds
US7186693B2 (en) 2001-08-16 2007-03-06 Kimberly - Clark Worldwide, Inc. Metalloproteinase inhibitors for wound healing
US6906036B2 (en) 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US7094754B2 (en) 2001-08-16 2006-08-22 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
DE10217677A1 (de) 2002-04-19 2003-11-06 Bayer Ag Verwendung von Aufhellern zur Herstellung von Streichmassen
US7148194B2 (en) 2002-12-30 2006-12-12 Kimberly-Clark Worldwide, Inc. Method to increase fibronectin
US7189700B2 (en) 2003-06-20 2007-03-13 Kimberly-Clark Worldwide, Inc. Anti-chrondrosarcoma compounds
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
DK1782068T3 (da) * 2004-07-23 2010-08-02 Ct De Rech Public De La Sante Overvågning af hjertesvigt
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
RU2007133660A (ru) * 2005-02-09 2009-03-20 Дженентек, Инк. (Us) Ингибирование шеддинга her2 антагонистами матриксной металлопротеиназы
US7504225B2 (en) * 2005-05-12 2009-03-17 Applied Genomics, Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
RU2304782C1 (ru) * 2005-12-28 2007-08-20 Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М. Сеченова Способ прогнозирования рецидива эндометриоидной кисты яичника
ES2567079T3 (es) 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
AU2010236222B2 (en) * 2009-04-16 2015-10-15 Momenta Pharmaceuticals, Inc. Methods of assessing activity of a polysaccharide composition
US9046522B2 (en) * 2009-07-24 2015-06-02 Geadic Biotec, Aie Markers for endometrial cancer
BR112012026542A2 (pt) 2010-04-16 2016-07-12 Momenta Pharmaceuticals Inc abordagem seletiva de tecido
RU2430371C1 (ru) * 2010-04-26 2011-09-27 Учреждение Российской академии наук Институт ядерной физики им. Г.И. Будкера Сибирского отделения РАН (ИЯФ СО РАН) Способ дифференциальной диагностики и прогноза миомы и рака эндометрия
CA2795868A1 (en) 2010-06-17 2011-12-22 Momenta Pharmaceuticals, Inc. Methods and compositions for modulating hair growth
US8455624B2 (en) * 2011-06-03 2013-06-04 University Of South Alabama Methods and compositions for detecting endometrial or ovarian cancer
CN107389936A (zh) * 2011-09-22 2017-11-24 斯隆－凯特林纪念癌症中心 检测卵巢癌
ES2691404T3 (es) * 2012-01-31 2018-11-27 SPEISER, Paul Diagnóstico no invasivo del cáncer
JP2016520613A (ja) 2013-05-28 2016-07-14 モメンタ ファーマシューティカルズ インコーポレイテッド 薬学的組成物
AU2015283811A1 (en) * 2014-07-02 2017-02-09 Bionomics Limited Predictive biomarkers
CA2975737A1 (en) * 2015-02-06 2016-08-11 Quest Diagnostics Investments Llc Compositions and methods for determining endometrial cancer prognosis
EP3452829B1 (en) * 2016-05-04 2024-01-24 Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca Perm as marker of endometrial cancer
IN202021002695A (https=) 2020-01-21 2021-07-23
CN112961921B (zh) * 2021-03-26 2022-07-01 中国医学科学院北京协和医院 一种用于判断早期子宫内膜癌预后的制剂及复发风险模型

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280106A (en) * 1988-05-20 1994-01-18 Liotta Lance A Matrix metalloproteinase peptides: role in diagnosis and therapy
US5324634A (en) 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
WO1994005807A1 (en) * 1992-08-28 1994-03-17 Dickson Robert B Matrix-degrading metalloproteinase
EP0674710B1 (en) * 1992-11-16 2003-05-02 Cancer Research Fund Of Contra Costa Peptides with broad neoplastic specificity

Also Published As

Publication number Publication date
DE69835010D1 (de) 2006-08-03
JP4183757B2 (ja) 2008-11-19
JP2002501613A (ja) 2002-01-15
CA2284099A1 (en) 1998-10-01
ATE331039T1 (de) 2006-07-15
MY119567A (en) 2005-06-30
EP0979304B1 (en) 2006-06-21
CA2284099C (en) 2010-04-27
EP0979304A1 (en) 2000-02-16
ES2268767T3 (es) 2007-03-16
US6607894B1 (en) 2003-08-19
EP0979304A4 (en) 2003-06-11
CN1257550A (zh) 2000-06-21
ZA982403B (en) 1998-10-21
AUPO573697A0 (en) 1997-04-10
JP2007202556A (ja) 2007-08-16
WO1998042865A1 (en) 1998-10-01
NZ337868A (en) 2002-05-31
KR20010006344A (ko) 2001-01-26

Similar Documents

Publication Publication Date Title
DE69835010T2 (de) Feststellung von endometriumkrebs
Tosoni et al. Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer
Kheir et al. Prognostic significance of DNA aneuploidy in stage I cutaneous melanoma
DE602004008889T2 (de) Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs
Temple et al. Mohs micrographic surgery in the treatment of lentigo maligna and melanoma
Pattern Jr Diagnostic cytopathology of the uterine cervix
Bianco Jr et al. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade.
DE69829198T2 (de) Nachweis von zellwachstumabnormalität
Woźna-Wysocka et al. Morphological changes in bitches endometrium affected by cystic endometrial hyperplasia-pyometra complex–the value of histopathological examination
King et al. Nipple aspirate cytology for the study of breast cancer precursors
Gagné et al. Development of a nonsurgical diagnostic tool for endometriosis based on the detection of endometrial leukocyte subsets and serum CA-125 levels
Hemstreet III et al. Identification of a high risk subgroup of grade 1 transitional cell carcinoma using image analysis based deoxyribonucleic acid ploidy analysis of tumor tissue
Sauter et al. Biologic markers of risk in nipple aspirate fluid are associated with residual cancer and tumour size
Klein et al. Flow cytometry of normal and nonneoplastic diseases of the bladder: An estimate of the false positive rate
Scolyer et al. Pathology of melanoma
Stoll et al. Prognostic importance of the expression of CD44 splice variants in oral squamous cell carcinomas
Jones et al. Investigation of expression of 5T4 antigen in cervical cancer
Klein et al. Flow cytometry followup of patients with low stage bladder tumors
DE60119731T2 (de) Immunologisches test und satz zur diagnose von prostatadenokarzinom
Zalles et al. Comparison of cytomorphology in specimens obtained by random periareolar fine needle aspiration and ductal lavage from women at high risk for development of breast cancer
Harlow et al. Diagnostic utility of DNA content flow cytometry in follicular neoplasms of the thyroid
Poh et al. Prostate-specific antigen in breast disease
AU728286B2 (en) Detection of endometrial cancer
MXPA99008616A (en) Detection of endometrial cancer
DE60027373T2 (de) Verfahren zur Bestimmung der Effektivität der Proteasen Inhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition